Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.34 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8642269 | 0.94 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL26664353 | 0.87 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL3476782 | 0.86 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL25399233 | 0.80 | P2RY2 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL992734 | 0.79 | DUT (0.30) | — | |
| SCHEMBL31548917 | 0.78 | P2RY2 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6761759 | 0.77 | TDP1 (0.34) | P2RY14 | |
| SCHEMBL25400566 | 0.77 | POLB (0.39) | — | |
| SCHEMBL28252054 | 0.77 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL7776582 | 0.76 | SLC28A1 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131908-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-9725479-B2 | 5′-end derivatives | IONIS PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | BANK OF AMERICA, N.A. | 2015-03-19 | — | — | US | disclosed |
| US-8927513-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130323836-A1 | 5'-END DERIVATIVES | ISIS PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011005860-A2 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | SLC28A1 200/4885SLC28A2 186/4885SLC29A1 127/4885 |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | SLC28A1 203/4885SLC28A2 187/4885SLC29A1 139/4885 |
| US-20130323836-A1 | 5'-END DERIVATIVES | NSUN2, RNGTT, RNMT | SLC28A1 1825/4885SLC28A2 1880/4885SLC29A1 1533/4885 |
| US-10131908-B2 | 5′ phosphate mimics | NSUN2, RNGTT, RNMT | SLC28A1 207/4885SLC28A2 195/4885SLC29A1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.